Oxybutynin Chloride
Product Images NDC 10135-611

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Oxybutynin Chloride (NDC 10135-611). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Marlex Pharmaceuticals Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

The Structural Formula Of Oxybutynin Chloride (Oxybutynin Chloride 01)

Chemical structure of the active ingredient Oxybutynin Chloride, showing its molecular arrangement including aromatic rings, ester linkage, alkynyl chain, and diethylamino group with hydrochloride salt.*

FDA Label Image

Figure 1: Mean R-oxybutynin Plasma Concentrations Following A Single Dose Of Oxybutynin Chloride 10 mg And Oxybutynin 5 mg Administered Every 8 Hours (n=23 For Each Treatment). (Oxybutynin Chloride 02)

A line graph depicting mean plasma R-Oxybutynin concentration (ng/mL) over time (hours) comparing two dosing regimens of Oxybutynin Chloride: 10 mg once daily (QD) and 5 mg three times daily (TID). Data points include variability bars indicating concentration fluctuations over 24 hours.*

FDA Label Image

The Structural Formula Of Mean Steady-state (± Sd) R-oxybutynin Plasma Concentrations Following Administration Of 5 To 20 mg Oxybutynin Chloride Once Daily In Children Aged 5 To 15. Plot Represents All Available Data Normalized To An Equivalent Of Oxybutynin Chloride 5 mg Once Daily. (Oxybutynin Chloride 03)

A line graph showing mean R-oxybutynin plasma concentration (ng/mL) over time (hours). The Y-axis represents concentration from 0.0 to 2.0 ng/mL, and the X-axis shows time points up to 24 hours. Data points include error bars indicating variability in measurements.*

FDA Label Image

Mean Change (sd) In Episodes Per Week From Baseline (Oxybutynin Chloride 04)

A horizontal error bar chart comparing the mean change with standard deviation in episodes per week from baseline for Oxybutynin Chloride and placebo. The x-axis ranges from -40 to 40, showing numerical data points for both groups illustrating treatment effect variability.*

FDA Label Image

Mean Change (sd) In Episodes Per Week From Baseline (Oxybutynin Chloride 05)

A horizontal bar chart comparing the mean change with standard deviation in episodes per week from baseline for Oxybutynin Chloride and oxybutynin. The x-axis ranges from -40 to 40, displaying data points around -20 to -25 for the two substances.*

FDA Label Image

Mean Change (sd) In Episodes Per Week From Baseline (Oxybutynin Chloride 06)

A horizontal error bar chart showing the mean change (±SD) in episodes per week from baseline for oxybutynin chloride and oxybutynin. The x-axis ranges from -40 to 40, with data points indicating negative mean changes for both substances, suggesting a reduction in episodes per week.*

FDA Label Image

Principal Display Panelndc 10135-0609-01marlexoxybutynin Chlorideextended- Releasetablets, Usp5 mgrx Only100 Tablets (Oxybutynin Chloride 07)

Label for Oxybutynin Chloride Extended-Release Tablets, USP, 5 mg strength by Marlex Pharmaceuticals, Inc. The label indicates a package size of 100 tablets. It includes storage instructions and manufacturing details stating it is made in the USA and distributed by Marlex Pharmaceuticals in New Castle, DE.*

FDA Label Image

Principal Display Panelndc 10135-0609-05marlexoxybutynin Chlorideextended- Releasetablets, Usp5 mgrx Only500 Tablets (Oxybutynin Chloride 08)

Label for Oxybutynin Chloride Extended-Release Tablets, USP 5 mg by Marlex Pharmaceuticals Inc. The label states the product contains 5 mg of oxybutynin chloride in a controlled-release formulation. It includes storage instructions, quantity of 500 tablets, and indicates the product is Rx only. The label shows the NDC number 10135-0609-05 and manufacturer details in New Castle, DE, USA.*

FDA Label Image

Principal Display Panelndc 10135-0610-01marlexoxybutynin Chlorideextended- Releasetablets, Usp10 mgrx Only100 Tablets (Oxybutynin Chloride 09)

Oxybutynin Chloride Extended-Release Tablets USP 10 mg label by Marlex Pharmaceuticals, Inc. The label indicates a package size of 100 tablets, prescription only. Storage instructions, barcode, and manufacturer information are visible, including the address in New Castle, DE, USA.*

FDA Label Image

Principal Display Panelndc 10135-0610-05marlexoxybutynin Chlorideextended- Releasetablets, Usp10 mgrx Only500 Tablets (Oxybutynin Chloride 0a)

Label for Oxybutynin Chloride Extended-Release Tablets, USP 10 mg by Marlex Pharmaceuticals Inc. The label includes storage instructions, dosage note to see package insert, and manufacturer information. It indicates the package contains 500 tablets, marked as Rx only, and displays the NDC number 10135-0610-05 along with a barcode.*

FDA Label Image

Principal Display Panelndc 10135-0611-01marlexoxybutynin Chlorideextended- Releasetablets, Usp15 mgrx Only100 Tablets (Oxybutynin Chloride 0b)

Label for Oxybutynin Chloride Extended-Release Tablets, USP 15 mg by Marlex Pharmaceuticals Inc. The label states the product contains extended-release 15 mg oxybutynin chloride tablets. It is prescription only and the package contains 100 tablets. Storage instructions and manufacturer details are included.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.